Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

Effect of oral and vaginal hormonal contraceptives on inflammatory blood biomarkers.

Divani AA, Luo X, Datta YH, Flaherty JD, Panoskaltsis-Mortari A.

Mediators Inflamm. 2015;2015:379501. doi: 10.1155/2015/379501. Epub 2015 Mar 16.

2.

Targeting Syk Activated B-cells in murine and human chronic graft-versus-host disease.

Flynn R, Allen JL, Luznik L, MacDonald KP, Paz K, Alexander KA, Vulic A, Du J, Panoskaltsis-Mortari A, Taylor PA, Poe JC, Serody JS, Murphy WJ, Hill GR, Maillard I, Koreth J, Cutler CS, Soiffer RJ, Antin JH, Ritz J, Chao NJ, Clynes RA, Sarantopoulos S, Blazar BR.

Blood. 2015 Apr 7. pii: blood-2014-08-595470. [Epub ahead of print]

PMID:
25852057
3.

B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality.

Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR.

Blood. 2015 Mar 26. pii: blood-2014-09-603357. [Epub ahead of print]

PMID:
25814530
4.

Circulating Angiogenic Factors associated with Response and Survival in Patients with Acute Graft-versus-Host Disease: Results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.

Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F, DeFor TE, Vercellotti GM, Slungaard A, MacMillan ML, Cooley SA, Blazar BR, Panoskaltsis-Mortari A, Weisdorf DJ.

Biol Blood Marrow Transplant. 2015 Mar 7. pii: S1083-8791(15)00125-1. doi: 10.1016/j.bbmt.2015.02.018. [Epub ahead of print]

5.

Bioreactor Development for Lung Tissue Engineering.

Panoskaltsis-Mortari A.

Curr Transplant Rep. 2015 Mar;2(1):90-97.

PMID:
25729638
6.

MSC therapy attenuates obliterative bronchiolitis after murine bone marrow transplant.

Raza K, Larsen T, Samaratunga N, Price AP, Meyer C, Matson A, Ehrhardt MJ, Fogas S, Tolar J, Hertz MI, Panoskaltsis-Mortari A.

PLoS One. 2014 Oct 1;9(10):e109034. doi: 10.1371/journal.pone.0109034. eCollection 2014.

7.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR.

J Clin Invest. 2014 Nov;124(11):4867-76. doi: 10.1172/JCI75328. Epub 2014 Oct 1.

8.

Can biomarkers differentiate pain and no pain subgroups of nonverbal children with cerebral palsy? A preliminary investigation based on noninvasive saliva sampling.

Symons FJ, ElGhazi I, Reilly BG, Barney CC, Hanson L, Panoskaltsis-Mortari A, Armitage IM, Wilcox GL.

Pain Med. 2015 Feb;16(2):249-56. doi: 10.1111/pme.12545. Epub 2014 Sep 19.

9.

Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.

Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, Luznik L.

Blood. 2014 Sep 25;124(13):2131-41. doi: 10.1182/blood-2013-10-525873. Epub 2014 Aug 18.

PMID:
25139358
10.

Automated decellularization of intact, human-sized lungs for tissue engineering.

Price AP, Godin LM, Domek A, Cotter T, D'Cunha J, Taylor DA, Panoskaltsis-Mortari A.

Tissue Eng Part C Methods. 2015 Jan;21(1):94-103. doi: 10.1089/ten.TEC.2013.0756.

11.

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans.

Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, MacDonald KP, Hill GR, Blazar BR.

Blood. 2014 Jun 19;123(25):3988-98. doi: 10.1182/blood-2014-03-562231. Epub 2014 May 12.

PMID:
24820310
12.

Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Fulton LM, Taylor NA, Coghill JM, West ML, Föger N, Bear JE, Baldwin AS, Panoskaltsis-Mortari A, Serody JS.

Eur J Immunol. 2014 Jun;44(6):1662-71. doi: 10.1002/eji.201344155.

PMID:
24752751
13.

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.

Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, Curtsinger J, Panoskaltsis-Mortari A, Lewis D, Hippen K, McGlave P, Weisdorf DJ, Blazar BR, Miller JS.

Blood. 2014 Jun 19;123(25):3855-63. doi: 10.1182/blood-2013-10-532531. Epub 2014 Apr 9.

PMID:
24719405
14.

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality.

Saha A, Aoyama K, Taylor PA, Koehn BH, Veenstra RG, Panoskaltsis-Mortari A, Munn DH, Murphy WJ, Azuma M, Yagita H, Fife BT, Sayegh MH, Najafian N, Socie G, Ahmed R, Freeman GJ, Sharpe AH, Blazar BR.

Blood. 2013 Oct 24;122(17):3062-73. doi: 10.1182/blood-2013-05-500801. Epub 2013 Sep 12.

15.

Club cell secretory protein improves survival in a murine obliterative bronchiolitis model.

Wendt C, Tram K, Price A, England K, Stiehm A, Panoskaltsis-Mortari A.

Am J Physiol Lung Cell Mol Physiol. 2013 Nov 1;305(9):L642-50. doi: 10.1152/ajplung.00021.2013. Epub 2013 Aug 30.

16.

Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration.

Aoyama K, Saha A, Tolar J, Riddle MJ, Veenstra RG, Taylor PA, Blomhoff R, Panoskaltsis-Mortari A, Klebanoff CA, Socié G, Munn DH, Murphy WJ, Serody JS, Fulton LM, Teshima T, Chandraratna RA, Dmitrovsky E, Guo Y, Noelle RJ, Blazar BR.

Blood. 2013 Sep 19;122(12):2125-34. doi: 10.1182/blood-2012-11-470252. Epub 2013 Jun 27.

17.

CC chemokine receptor 8 potentiates donor Treg survival and is critical for the prevention of murine graft-versus-host disease.

Coghill JM, Fowler KA, West ML, Fulton LM, van Deventer H, McKinnon KP, Vincent BG, Lin K, Panoskaltsis-Mortari A, Cook DN, Blazar BR, Serody JS.

Blood. 2013 Aug 1;122(5):825-36. doi: 10.1182/blood-2012-06-435735. Epub 2013 Jun 24.

18.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

Gynecol Oncol. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. Epub 2013 May 27.

19.

Innate immune function and mortality in critically ill children with influenza: a multicenter study.

Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, Shay DK, Nateri J, Greathouse K, Sullivan R, Tran T, Keisling S, Randolph AG; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network PICFlu Study Investigators.

Crit Care Med. 2013 Jan;41(1):224-36. doi: 10.1097/CCM.0b013e318267633c.

20.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS.

Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk